PLS Research Library

Primary lateral sclerosis is a rare disease. Research moves slowly, journal access is expensive, and the studies that exist are scattered across dozens of publications. This library gathers the most important research on PLS into one place — with plain-language summaries alongside the clinical detail.

A living PLS research library

PLS affects an estimated 1,500 to 3,000 people in the United States — a small enough population that it has historically struggled to attract the research investment, clinical trial infrastructure, and dedicated funding that more common neurological diseases receive. The result is that meaningful studies exist, but they are hard to find, difficult to interpret without specialist training, and rarely compiled in any one place for patients and families.

This library is built from 1,186 peer-reviewed sources synthesized across 187 topic pages in the research database underlying this site. It is organized by topic, written for a general audience, and updated as new studies emerge. Every summary preserves the key numbers, cohort sizes, and findings from the original study — not just the headline conclusion.

The goal is not to replace your neurologist's guidance. It is to give you and your family the background to have more informed conversations, understand what a study actually showed (versus what it was interpreted to show), and know where the genuine uncertainties lie.

How this library is organized

The research is divided into five topic areas, each on its own page:

• Natural history — What happens over time in PLS. How fast does it progress? What do large cohort studies tell us about survival and functional decline? This section covers the foundational natural history studies that established what PLS looks like across populations.
• Biomarkers — Blood and imaging markers that reflect disease activity. Neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH), glial fibrillary acidic protein (GFAP), and MRI-based markers including the corticospinal tract signal and the wine glass sign.
• Spasticity research — The evidence base for spasticity treatment in PLS. Randomized trials of baclofen versus tizanidine, long-term follow-up data on intrathecal baclofen pumps, botulinum toxin, NICE guideline evidence, and physical therapy approaches.
• Drug trials — Why PLS has so few dedicated treatment trials, what has been tried, what failed and why, and how the broader motor neuron disease drug pipeline intersects with PLS.
• Genetics — The genetic architecture of PLS. Adult PLS is almost always sporadic. Juvenile PLS is a distinct genetic disease caused by ALS2 mutations. This section covers what whole genome sequencing has revealed and where PLS sits relative to ALS and hereditary spastic paraplegia at the genetic level.

How to read a research entry

Each study in the library is structured the same way. First, the citation: authors, year, journal, and sample size. Then three short sections:

• What they did — the study design, who was enrolled, what was measured, and over what period.
• What they found — the actual numbers, not just the direction of the result.
• Why it matters — what this study changes or confirms in how we understand PLS.

Where a study is limited — small sample, retrospective design, single-center data — that is noted. PLS research is often small-scale by necessity. A 40-patient prospective cohort can still be a landmark study when the alternative is no data at all.

The source base

The research database behind this site currently synthesizes 1,186 peer-reviewed studies, clinical guidelines, and registry data sources. The studies represented in this library were selected based on relevance to PLS specifically, quality of evidence, and clinical significance. Priority was given to prospective studies, randomized controlled trials where they exist, and major cohort studies from recognized PLS research centers — including Mayo Clinic, Johns Hopkins, the Northeast ALS Consortium (NEALS), and the Oxford Motor Neuron Disease Care and Research Centre.

Where PLS-specific data does not exist for a topic — spasticity pharmacology is the clearest example — the library draws on the best available evidence from related populations (multiple sclerosis, hereditary spastic paraplegia, ALS) and notes where extrapolation is occurring.

How updates happen

New PLS research is published infrequently. The major journals to watch are Neurology, Annals of Neurology, Journal of Neurology, Neurosurgery & Psychiatry, and Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. The PLS Natural History Study — a prospective multicenter study funded by the CDC and running at Mayo Clinic and Johns Hopkins — is the most active current source of new primary data. When significant new studies are published, this library is updated.

If you are aware of a study that should be included and is not, the contact information for this site is on the homepage.

Browse by topic

• Natural History Studies — Cohort data on PLS progression, survival, and functional decline
• Biomarker Research — NfL, pNfH, GFAP, and MRI markers
• Spasticity Research — Treatment trials and clinical evidence
• Drug Trials — PLS-specific trials and the broader MND pipeline
• Genetics Research — Sporadic PLS, ALS2, and genomic studies